Annovis Bio, Inc.
Annovis Bio, Inc. (ANVS): 4 pipeline candidates · 2 upcoming catalysts · ~5 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
4.7 months
D/E 4.20 · 0% dilution
Lead: Phase 3
4 candidates
2 upcoming, next in ~714d
4 buys · 0 sells (180d)
A transparent, data-derived signal for Annovis Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$74.0M
Cash
$14.2M
Quarterly Burn
$9.0M
Runway
4.7 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| ANVS301 | Phase 1 |
| ANVS405 | Preclinical |
| buntanetap | Phase 3 |
| buntanetap/posiphen | Phase 2/Phase 3 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
57
Total value held
$13.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,744,762 | $3.9M |
| marshall wace, llp | 1,187,499 | $2.6M |
| two sigma investments, lp | 627,659 | $1.4M |
| susquehanna international group, llp | 541,036 | $1.2M |
| renaissance technologies llc | 347,600 | $775K |
| geode capital management, llc | 247,513 | $552K |
| northern trust corp | 141,730 | $316K |
| blackrock, inc. | 139,533 | $311K |
| vanguard fiduciary trust co | 132,042 | $294K |
| citadel advisors llc | 104,900 | $234K |
Showing top 10 of 57 institutional holders of Annovis Bio, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Annovis Bio, Inc.'s pipeline?
Annovis Bio, Inc. (ANVS) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Annovis Bio, Inc.'s lead drug candidate?
Annovis Bio, Inc.'s most advanced tracked candidate is ANVS301 (Phase 1) for Advanced Alzheimer's disease and dementia.
What is Annovis Bio, Inc.'s next catalyst?
Annovis Bio, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial I" — expected June 1, 2028.
What is Annovis Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Annovis Bio, Inc. has approximately 4.7 months of cash runway.
What is Annovis Bio, Inc.'s market capitalization?
Annovis Bio, Inc.'s market capitalization is approximately $74.0M.
Get the full picture on Annovis Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.